Physician profile
John Christopher Smith
NPI 1760543797
$2,530.10
in general payments reported to CMS, 2019-2025
27 companies · $282 in 2025
The $282 reported for 2025 was more than what 83% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $197 · 2020: $168 · 2021: $513 · 2022: $522 · 2023: $425 · 2024: $422 · 2025: $282.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,129.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,129.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $559.77 | 2021-2025 | Azstarys |
| Tris Pharma INC | $272.15 | 2020-2024 | Dyanavel Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $261.41 | 2020-2022 | |
| Sanofi Pasteur INC. | $198.05 | 2019-2025 | |
| Ironshore Pharmaceuticals INC. | $178.14 | 2019-2024 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $172.80 | 2021-2025 | Qelbree |
| Merck Sharp & Dohme LLC | $125.77 | 2020-2024 | Gardasil 9, Vaxneuvance, Proquad |
| Glaxosmithkline, LLC. | $90.70 | 2019-2022 | |
| Adlon Therapeutics L.P. | $87.98 | 2021 | |
| Cranial Technologies, INC | $87.95 | 2019-2025 | Doc Band |
| Pharming Healthcare, INC. | $66.45 | 2023-2024 | Ruconest |
| Sanofi-Aventis U.S. LLC | $65.65 | 2024 | |
| Shire North American Group INC | $64.91 | 2019 | |
| Collegium Pharmaceutical, INC. | $52.19 | 2025 | Jornay Pm |
| Sobi, INC | $37.81 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ultragenyx Pharmaceutical INC. | $34.42 | 2021-2022 | |
| Pfizer INC. | $27.03 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $21.23 | 2023 | Flumist Quadrivalent |
| Ironwood Pharmaceuticals, INC | $16.75 | 2024 | |
| Neurelis, INC. | $15.72 | 2023 | Valtoco |
| Medtronic Vascular, INC. | $15.48 | 2020 | |
| Arbor Pharmaceuticals, INC. | $14.90 | 2019 | |
| Verrica Pharmaceuticals INC. | $14.47 | 2023 | Ycanth |
| Kaleo, INC. | $13.65 | 2020 | |
| Mission Pharmacal Company | $11.98 | 2019 | |
| Genentech USA, INC. | $11.59 | 2021 | |
| Abbvie INC. | $11.15 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.